×
UNITY Biotechnology Net Profit Margin 2017-2025 | UNBX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
UNITY Biotechnology net profit margin from 2017 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue.
View More
UNITY Biotechnology Net Profit Margin 2017-2025 | UNBX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
UNITY Biotechnology net profit margin from 2017 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$247.9B
Amgen (AMGN)
$155B
Gilead Sciences (GILD)
$141.4B
Vertex Pharmaceuticals (VRTX)
$99.8B
Bristol Myers Squibb (BMY)
$96.9B
GSK (GSK)
$81.3B
CSL (CSLLY)
$67.8B
Regeneron Pharmaceuticals (REGN)
$62.2B
Alnylam Pharmaceuticals (ALNY)
$59.5B
Argenex SE (ARGX)
$43.3B
Insmed (INSM)
$28.4B
BioNTech SE (BNTX)
$24.8B
Royalty Pharma (RPRX)
$21B
Biogen (BIIB)
$20B
Incyte (INCY)
$16.6B
Genmab (GNMSF)
$16B
Genmab (GMAB)
$15.9B
Illumina (ILMN)
$15.3B
Ascendis Pharma (ASND)
$11.8B
BioMarin Pharmaceutical (BMRN)
$11.3B
Swedish Orphan Biovitrum (BIOVF)
$10.9B
QIAGEN (QGEN)
$10.7B
Exelixis (EXEL)
$10.4B
Moderna (MRNA)
$9.8B
Verona Pharma American Depositary Share (VRNA)
$9.1B
Exact Sciences (EXAS)
$8.8B
Bio-Techne Corp (TECH)
$8.8B
Halozyme Therapeutics (HALO)
$8.6B
Blueprint Medicines (BPMC)
$8.3B
Roivant Sciences (ROIV)
$8.2B